Group 1 - The company held its second extraordinary general meeting on November 14, 2025, where it approved the cancellation of the supervisory board, increased the number of board seats, and revised the Articles of Association [2][13] - Wang Binchao was elected as the employee director of the third board of directors, with a term lasting until the end of the current board's term [2][5] - The board of directors now consists of 9 members, including 1 employee director, complying with relevant laws and regulations [2][3] Group 2 - The third board of directors' fourth meeting was held on November 14, 2025, where the adjustment of the audit committee members was approved [3][8] - The audit committee now includes Liu Shujin as the chairman, Xu Lin, and Wang Binchao [3][9] - The meeting was attended by all 9 directors, and the resolutions passed were deemed legal and effective [7][8] Group 3 - The company approved an investment of 323.2079 million yuan for the construction of a "High-Precision and Intelligent Pharmaceutical Industrialization Project" through its wholly-owned subsidiary [10] - The project is expected to be completed by April 2028 [10]
北京福元医药股份有限公司 关于选举职工董事及调整审计委员会成员的公告